 |
|
Relationship Between Obesity and B-Type Natriuretic Peptide Levels
James McCord, MD;
Brian J. Mundy, MD;
Michael P. Hudson, MD, MHS;
Alan S. Maisel, MD;
Judd E. Hollander, MD;
William T. Abraham, MD;
Philip G. Steg, MD;
Torbjørn Omland, MD, MPH, PhD;
Cathrine W. Knudsen, MD;
Keisha R. Sandberg, MPH;
Peter A. McCullough, MD, MPH; for the Breathing Not Properly Multinational Study Investigators
Arch Intern Med. 2004;164:2247-2252.
ABSTRACT
| |
Background The relationships among B-type natriuretic peptide (BNP) levels, body mass index (BMI), and congestive heart failure (CHF) as an emergency diagnosis are unknown.
Methods Of 1586 participants in the Breathing Not Properly Multinational Study who had acute dyspnea, 1369 (86.3%) had BNP values and self-reported height and weight. Two independent cardiologists masked to the BNP results adjudicated the final diagnosis.
Results Congestive heart failure was found in 46% of participants. Individuals with higher BMIs were younger and had more frequent edema on examination but were equally as likely to have CHF vs noncardiac sources of dyspnea. A nearly 3-fold difference was seen in mean ± SD BNP values at the low and high extremes of the BMI groupings (516.7 ± 505.9 vs 176.3 ± 270.5 pg/mL, respectively; P< .001). The correlations between BMI and log BNP among those with and without CHF were r = –0.34 and r = –0.21, respectively (P< .001 for both). Multivariate analysis for the outcome of log BNP among a small subset with CHF (n = 62) found that Framingham score (P = .002), estimated glomerular filtration rate (P = .007), female sex (P = .03), New York Heart Association functional class (P = .09), and third heart sound (P = .08) were independent predictors. However, BMI was not found to be independently related to log BNP (P = .59).
Conclusions In patients with and without CHF, BNP levels are inversely related to BMI. When considering demographics, severity of disease, and renal function, BMI is not independently related to BNP levels in a small subgroup when detailed information about CHF severity is known.
INTRODUCTION
The prevalence of obesity has increased dramatically worldwide during the past 3 decades.1-5 Approximately 65% of Americans are overweight or obese,6 and the prevalence of morbid obesity (body mass index [BMI] [calculated as weight in kilograms divided by the square of height in meters]  40) has more than doubled in the past decade.6 Similarly, there is an epidemic of congestive heart failure (CHF), with 5 million individuals with CHF in the United States and 500 000 new cases diagnosed each year.7-8 Clinical encounters in obese patients with dyspnea are becoming commonplace. Furthermore, obesity has been independently associated with incident CHF.9
B-type natriuretic peptide (BNP) is a cardiac neurohormone secreted from the ventricles in response to pressure overload.10 Levels of BNP are reliably elevated in patients with CHF, and they correlate with New York Heart Association functional classifications11 and prognosis.12-13 However, age and sex also affect BNP levels.14 We sought to characterize the relationships among BMI, BNP levels, and patients evaluated in the emergency department (ED) for possible CHF.
METHODS
PATIENT POPULATION
The Breathing Not Properly Multinational Study was an international 7-center prospective trial that evaluated the utility of BNP measurements for the diagnosis of CHF in the ED. The study design and results have been published elsewhere.11 The study was conducted between April 1, 1999, and December 31, 2000, and was approved by the institutional review board of each participating medical center. Briefly, 1666 patients older than 18 years presenting to the ED with the primary complaint of dyspnea were screened. Eighty patients met the exclusion criteria: advanced renal failure (dialysis or a glomerular filtration rate <15 mL/min per 1.732), acute coronary syndrome, or trauma. A total of 217 patients had missing BMI data, leaving 1369 patients for the final analysis.
MEASUREMENT OF BNP
During the initial evaluation in the ED, a 5-mL blood sample was collected in a tube containing potassium EDTA. B-type natriuretic peptide concentration was measured using a fluorescence immunoassay (Triage BNP Test; Biosite Inc, San Diego, Calif). The precision, analytical sensitivity, and stability characteristics of the assay have been described previously.15-16 Results of BNP measurement were masked to clinicians.
REFERENCE STANDARD FOR HEART FAILURE
Approximately 30 days after the initial ED visit, the ED record, inpatient record, discharge summary, chest radiography report, electrocardiogram at presentation, and all clinical test results were reviewed by 2 independent cardiologists at each study center. If agreement was achieved after reviewing all information, each case was categorized as (1) dyspnea due to CHF, (2) dyspnea with a noncardiac cause, or (3) history of CHF but dyspnea with a noncardiac cause. If agreement was not achieved, the end points committee adjudicated the cases. For binary analyses of CHF vs no CHF, groups 2 and 3 were combined. As previously reported in the overall study,11 cardiologists at each study center evaluated all clinical data, including echocardiograms with reported ejection fractions, in 689 cases (44.8%). There was initial agreement between the 2 cardiologists in 1374 cases (89.3%). The remaining 164 cases were adjudicated locally by the 2 cardiologists, with additional data from the treating physicians and review by the end points committee if disagreement remained. The diagnosis of CHF (n = 722) was supported by positive NHANES (National Health and Nutrition Examination Survey) and Framingham scores in 599 (83.0%) and 621 (86.0%) cases, respectively. The cardiologists reported support for the diagnosis of CHF by chest radiography in 587 cases (81.3%), echocardiography in 448 (62.0%), nuclear ventriculography in 34 (4.7%), and cardiac catheterization in 55 (7.6%). In addition, the cardiologists reported that 490 patients with CHF (67.9%) had an expected response to CHF therapy. Conversely, 684 (91.4%) of the 748 patients without CHF had cumulative evidence from chest radiography, echocardiography, or ventriculography to suggest that CHF was not the cause of dyspnea. Overall, 36.5% of individuals with echocardiograms had preserved systolic function (ejection fraction >45%).
REPORTING OF BODY WEIGHT AND SIZE
Body height and weight were by self-report and by actual measurement, with variations by study center. Given the inherent differences in these measures and the confounding issue of edema and body weight accounted for by excess body fluid, a variety of measures were used: (1) body weight by self-report or actual weight (original database value); (2) estimated lean body weight from height using the following formulas: men—50 kg + 2.3 kg x [height (in inches) – 60], women—45.5 kg + 2.3 kg x [height (in inches) – 60]; (3) estimated lean body weight from height and weight as recorded in the database using the following formulas: men—[1.10 x weight (in kilograms)] – 128 [weight2/(100 x height [in meters])2], women—[1.07 x weight (in kilograms)] – 148 [weight2/(100 x height [in meters])2]; and (4) calculated body surface area (BSA) using the following formula: BSA (m2) = weight (in kilograms)0.51456 x height (in centimeters)0.42246 x 0.02350 (formula of Gehan and George).17-18 The following Pearson correlations were considered: database body weight x lean body weight from height, 0.35 (P< .001); database body weight x lean body weight from height and weight, 0.50 (P< .001); BMI x lean body weight from height, –0.08 (P = .002); and BMI x lean body weight from height and weight, 0.13 (P<.001). Accordingly, a lean BMI variable was constructed from the lean body weight estimated from height and weight (in kilograms) divided by the square of the height in meters and was considered as a secondary variable for analysis along with conventionally calculated BMI from the database height and weight.
STATISTICAL ANALYSIS
Univariate statistics were reported as mean ± SD or counts, with proportions as appropriate. The  2 test or 1-way analysis of variance was used to determine differences between groups. Because BNP levels were not normally distributed, the log BNP was used in correlations and regression models. The univariate relationships between measures of body size and log BNP were tested using the Pearson correlation. Multiple linear regression was used to analyze the strength of association between log BNP and BMI after adjusting for age, sex, history of CHF, New York Heart Association classification, and echocardiographic and other baseline factors not significant in the univariate analysis.
RESULTS
A total of 1369 participants had valid information for all direct and calculated variables. Patients were aged 63.4 ± 16.3 years; 54.8% were male; 45.1% were white and 49.7% were African American; and 46.2% had a final diagnosis of CHF and 53.8% had a final diagnosis of noncardiac dyspnea, primarily asthma or chronic obstructive pulmonary disease. The clinical characteristics are given in Table 1 by BMI classification: underweight (<20.0), normal (20.0-24.9), overweight (25.0-29.9), obese class I (30.0-34.9), obese class II (35.0-39.9), and obese class III (40.0). As seen in Table 1, patients who were overweight or obese were younger and had more frequent edema on examination but were equally as likely to have CHF vs noncardiac sources of dyspnea. The data in Table 1 also demonstrate that body weight as recorded in the database, not height, differed across the BMI categories and hence was the principal determinant of BMI. The mean and median BNP levels according to BMI for the study population are also given in Table 1. A nearly 3-fold difference was seen in mean BNP values at the extremes of the BMI groupings (516.7 ± 505.9 vs 176.3 ± 270.5 pg/mL for those with BMI <20.0 vs 40.0; P< .001). Among those with CHF and recorded ejection fractions in the database (n = 663), there was no trend for increasing rates of diastolic heart failure (ejection fraction >45%) according to BMI category (ejection fractions of 25.0%, 19.9%, 25.1%, 23.1%, 26.3%, and 32.1% for patients with a BMI <20.0, 20.0-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, and 40.0, respectively; P = .15).
|
|
|
|
Table 1. Baseline Characteristics of the 1369 Study Participants by BMI Category
|
|
|
Figure 1 and Figure 2 show scatterplots of log BNP and BMI in patients with and without CHF, respectively. Note that in patients with CHF, values are truncated owing to the upper measurable limit of BNP in the study of 1300 pg/mL. As shown, most BNP values at or above the normal range occurred in patients in the lower BMI categories. However, in individuals without CHF (Figure 2), BNP values are truncated at the lower range and extend from a BMI of 20 through 50. Table 2 gives the Pearson product moment correlations between the measures of body weight and log BNP for participants with and without CHF. The relationships between log BNP and measures of body size were stronger in individuals with CHF than in those without CHF. Figure 3 displays the frequency of markedly elevated (>1000 pg/mL) BNP levels by BMI category in participants with CHF, indicating a strong trend for those with lower body weight to have higher BNP values. Conversely, Figure 4 shows the frequency of low (<50 pg/mL) BNP values in participants without CHF according to BMI category. Except for participants with the lowest BMI (<20.0), more than 50% of each BMI category had BNP values of less than 50 pg/mL, which are considered in the normal range for patients with normal left ventricular function. The linear trend for higher rates of BNP values less than 50 pg/mL persisted even when the lowest BMI group was excluded (P = .004). The area under the receiver operating characteristic curve for BNP in the diagnosis of CHF was high and similar at 0.90, 0.92, and 0.89 for those with a BMI of less than 20.0, 20.0 to 24.9, and 25 or greater, respectively.
|
|
|
|
Figure 1. Scatterplot of log B-type natriuretic peptide (BNP) levels and body mass index (calculated as weight in kilograms divided by the square of height in meters) for individuals with congestive heart failure (r = –0.34; P < .001). The regression line of best fit is shown.
|
|
|
|
|
|
|
Figure 2. Scatterplot of log B-type natriuretic peptide (BNP) levels and body mass index (calculated as weight in kilograms divided by the square of height in meters) for individuals without congestive heart failure (r = –0.21; P < .001). The regression line of best fit is shown.
|
|
|
|
|
|
|
Table 2. Correlation Matrix of Log BNP and Body Measures of Height and Weight for Individuals With and Without CHF
|
|
|
|
|
|
|
Figure 3. Frequency of B-type natriuretic peptide (BNP) levels greater than 1000 pg/mL in individuals with congestive heart failure by body mass index (calculated as weight in kilograms divided by the square of height in meters) (P < .001 for trend).
|
|
|
|
|
|
|
Figure 4. Frequency of B-type natriuretic peptide (BNP) levels less than 50 pg/mL in individuals without congestive heart failure by body mass index (calculated as weight in kilograms divided by the square of height in meters) (P< .001 for trend).
|
|
|
Multivariate modeling was restricted to patients (n = 62) who had complete data on body measures, echocardiography, CHF severity, renal function, and other known predictors of BNP levels. The distributions of those included and excluded from the multivariate analysis were the same, with mean BMI values of 28.7 ± 7.3 and 28.7 ± 8.4, respectively (P = .39). In addition, there was no difference between the skewness of the populations (1.4 vs 1.5). The results of the multivariate model for participants with CHF are given in Table 3. Known determinants of BNP levels, including sex (higher for women), estimated glomerular filtration (calculated from age, sex, serum creatinine level, and race using the Modification of Diet in Renal Disease 4-variable equation), CHF severity (reflected by the Framingham score and New York Heart Association functional classification), and the presence of a third heart sound, were independent predictors of log BNP. When adjusting for these factors, BMI was not an independent predictor. When the regressions were repeated with lean BMI, again, no independent association with log BNP was found. The model had an overall F statistic of 3.86 (P< .001).
|
|
|
|
Table 3. Independent Predictors of Log BNP in 62 Patients With CHF With Full Information About CHF Severity and Echocardiographic Data
|
|
|
COMMENT
This study demonstrated a modest univariate correlation with log BNP and BMI in individuals with acute dyspnea (r = –0.21 to –0.34). The results of our analysis suggest that this relationship is driven by the observation that patients with CHF and a smaller body size had greater frequencies of markedly elevated BNP values. This finding is in keeping with the observation that patients with CHF and a smaller body size have a greater degree of cardiac cachexia and higher mortality rates.18-21 Conversely, in individuals without CHF, lower levels of BNP tended to occur in participants with larger BMI values. Our multivariate analysis, in a very small subset, found that there was no independent relationship between BMI and BNP when we accounted for the known factors affecting BNP, such as sex; age-derived variables, including renal function; and CHF severity. There was an approximate 1:1 ratio of African Americans to whites in the BMI categories, but this ratio increased to almost 2:1 in the highest BMI categories. However, according to the multivariate analysis, African American race was not statistically significantly related to the measured BNP value. Our findings suggest that much of the inverse relationship between BMI and BNP can be explained by confounding, particularly by age in individuals without CHF and by the severity of disease in those with CHF. These observations are in agreement with those from previous studies14, 23 that demonstrated that BNP values are lower in patients who are younger and less ill.
The reason for the relationship between lower BMI and elevated BNP levels in patients with CHF is uncertain, but several possibilities exist. Cardiac cachexia has been a well-described condition associated with advanced CHF and, consistent with marked elevations of BNP concentration, portends a poor prognosis.23-24 Hence, the finding of very high levels of BNP in patients with CHF and low body weight can simply be explained by severity of disease. Another distinct possibility is misclassification of the cause of dyspnea in individuals determined to have CHF. Physical examination, chest radiography, and echocardiographic interpretation are particularly challenging in obese individuals, who are at higher risk of having CHF than nonobese individuals.25-30 Obese patients thought to have CHF with lower or normal BNP levels may not have had CHF as the actual cause of their dyspnea. This could in part explain why in other studies obese patients with CHF seem to have a better prognosis (the "obesity paradox").19 The diagnosis of diastolic CHF may be particularly susceptible to misdiagnosis in patients with obesity.31 However, we did not find higher rates of preserved systolic function in the higher BMI categories in patients with CHF. Finally, BNP level is, to a great extent, degraded by clearance receptors and neutral endopeptidase mostly located in the kidney but also found in the lungs, brain, heart, and peripheral vasculature.32-34 Adipose tissue may afford another source of available clearance receptors and neutral endopeptidase, leading to more rapid degradation of BNP. In addition, natriuretic peptides have recently been found35-36 to be lipolytic in adipose tissue; hence, higher BNP levels may have potentially facilitated weight loss and the lower body weights we observed in individuals with high BNP levels. Although speculative, this may in part explain the weak correlations between BMI and BNP levels in individuals without CHF.
There are several limitations to our study. First, self-reported height and weight were used to calculate BMI, which may have led to inaccuracies. However, we believe that the use of calculated lean BMI would have been even more problematic because it may not be accurate in the setting of cardiac cachexia. Second, there were many patients without echocardiographic data who, therefore, could not be included in the multivariate analysis (which included 62 of 1369). Finally, this study has many of the same limitations related to any study attempting to use a clinical diagnosis as a gold standard for a syndrome. The reviewing cardiologists had all possible medical records to review, but we acknowledge that misclassification of the final diagnosis was possible but was likely to be nonrandom and impossible to quantify in the absence of a more objective reference standard.
In conclusion, high levels of BNP in patients with low body weights and, likely, advanced CHF accounted for the inverse relationship between BNP levels and BMI. There does not seem to be an independent relationship between measures of body weight or size and BNP when all other factors are taken into account. Clinicians should be wary of the univariate relationship between BMI and BNP level that we have demonstrated in the present study.
| Breathing Not Properly Multinational Study Investigators
University of California, San Diego, Veteran’s Affairs Medical Center: study co-principal investigator—Alan S. Maisel, MD; site principal investigators—Radmila Kazanegra, MD; Patricia Hlavin, MD; Leslie A. Lenert, MD; and Padma Krishnaswamy, MD; and biostatistician—Paul Clopton, MS; Henry Ford Hospital: site principal investigators—Richard M. Nowak, MD, MBA, and James McCord, MD; and study coordinators—Michele Whitican, RN, and James Babiarz, RN; University of Pennsylvania: site principal investigators—Judd E. Hollander, MD; Howard C. Herrmann, MD; and Evan Loh, MD; and study coordinator—Frank D. Sites, RN, BSN; Hopital Bichat: site principal investigators—Philippe Duc, MD, and Philippe G. Steg, MD; and co-investigators—Marie Claude Aumont, MD; Valerie Beaumesnil, MD; Lamia Hafi, MD; Armelle Desplanques, MD; and Joelle Benessiano, MD; Ullevål University Hospital, Oslo, Norway: site principal investigators—Arne Westheim, MD, PhD; Torbjørn Omland, MD, PhD, MPH; and Cathrine Wold Knudsen, MD; and co-investigators—Alexandra Finsen, MD; Jon Sigurd Riis, MD; and Tor Ole Klemsdal MD, PhD; University of Cincinnati College of Medicine, Cincinnati, Ohio: site principal investigator—Alan B. Storrow, MD; University of Kentucky College of Medicine, Lexington: co-investigator—Sumant Lamba, MD; Ohio State University School of Medicine, Columbus: co-investigator—William T. Abraham, MD; Hartford Hospital, Hartford, Conn: site principal investigators—Alan H. B. Wu, PhD, and Alberto Perez, MD; University of Missouri–Kansas City School of Medicine, Truman Medical Center, and William Beaumont Hospital: study co-principal investigator—Peter A. McCullough, MD, MPH.
|
|
Accepted for Publication: January 9, 2004.
AUTHOR INFORMATION
Correspondence: Peter A. McCullough, MD, MPH, Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Beaumont Health Center, 4949 Coolidge Hwy, Royal Oak, MI 48073 (pmc975{at}yahoo.com).
Funding/Support: Triage BNP devices and meters and some financial support were provided by Biosite Inc.
Previous Presentation: This study was presented in part at the 52nd Scientific Sessions of the American College of Cardiology; March 30, 2003; Chicago, Ill.
Financial Disclosure: Drs McCord, Maisel, Omland, and McCullough are consultants to and Drs McCord, Maisel, Hollander, Omland, and McCullough have received research support from Biosite Inc.
Author Affiliations: Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, Mich (Drs McCord, Mundy, and Hudson); University of California, San Diego School of Medicine, San Diego Veterans Affairs Medical Center (Dr Maisel); Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia (Dr Hollander); Division of Cardiology, Ohio State University School of Medicine, Columbus (Dr Abraham); Hopital Bichat, Paris, France (Dr Steg); Department of Medicine, Akershus University Hospital, Nordbyhagen, Norway (Dr Omland); Department of Medicine, Ullevål University Hospital, Oslo, Norway (Dr Knudsen); Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Royal Oak, Mich (Ms Sandberg and Dr McCullough).
Group Information: A list of the Breathing Not Properly Multinational Study Investigators appears at the end of this file.
REFERENCES
| |
1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
FREE FULL TEXT
2. Lewis CE, Jacobs DR, McCreath H, et al. Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study (Coronary Artery Risk Development in Young Adults). Am J Epidemiol. 2000;151:1172-1181.
FREE FULL TEXT
3. Mokdad AH, Bowman BA, Ford ES, Vincor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
4. Mallard G, Charles MA, Thibult N, et al. Trends in the prevalence of obesity in the French adult population between 1980 and 1991. Int J Obes Relat Metab Disord. 1999;23:389-394.
FULL TEXT
|
ISI
| PUBMED
5. Martorell R, Khan LK, Hughes ML, Grummer-Strawn LM. Obesity in women from developing countries. Eur J Clin Nutr. 2000;54:247-252.
FULL TEXT
|
ISI
| PUBMED
6. Freedman DS, Khan LK, Serdula MK, et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002;288:1758-1761.
FREE FULL TEXT
7. Packer M, Cohn JN, eds. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83(suppl):1A-38A.
FULL TEXT
|
ISI
| PUBMED
8. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) Study. J Am Coll Cardiol. 2002;39:60-69.
FREE FULL TEXT
9. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313.
FREE FULL TEXT
10. Maeda K, Tsutamota T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825-832.
FULL TEXT
|
ISI
| PUBMED
11. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
FREE FULL TEXT
12. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 2002;39:131-138.
FULL TEXT
|
ISI
| PUBMED
13. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392-2397.
FREE FULL TEXT
14. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254-258.
FULL TEXT
|
ISI
| PUBMED
15. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients with dyspnea. J Am Coll Cardiol. 2002;39:202-209.
FREE FULL TEXT
16. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med. 2001;39:571-588.
FULL TEXT
|
ISI
| PUBMED
17. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970;54:225-235.
ISI
| PUBMED
18. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49:163-175.
ISI
| PUBMED
19. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789-795.
FREE FULL TEXT
20. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J. 2001;22:1318-1327.
FREE FULL TEXT
21. Lavie CJ, Osman AF, Milani RV, et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003;91:891-894.
FULL TEXT
|
ISI
| PUBMED
22. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett SJ Jr. Plasma brain natriuretic concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976-982.
FREE FULL TEXT
23. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85:51-66.
FULL TEXT
|
ISI
| PUBMED
24. Doehner W, Anker SD. Cardiac cachexia in early literature: a review of research prior to MEDLINE. Int J Cardiol. 2002;85:7-14.
FULL TEXT
|
ISI
| PUBMED
25. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute–National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation. 2002;105:2923-2928.
FREE FULL TEXT
26. Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002;39:138-141.
FREE FULL TEXT
27. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
FREE FULL TEXT
28. Wilson PWF, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk. Arch Intern Med. 2002;162:1867-1872.
FREE FULL TEXT
29. Abbasi F, Brown WB Jr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002;40:937-943.
FREE FULL TEXT
30. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women. Arch Intern Med. 2001;161:996-1002.
FREE FULL TEXT
31. Caruana L, Petrie MC, Davie AP, et al. Do patients with suspected heart failure and preserved left ventricular function suffer from "diastolic heart failure" or from misdiagnosis? a prospective descriptive study. BMJ. 2000;321:215-218.
FREE FULL TEXT
32. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation. 2002;105:999-1003.
FREE FULL TEXT
33. Maki T, Nasa Y, Yamaguchi F, et al. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res. 2001;51:608-617.
FREE FULL TEXT
34. Smith MW, Espiner EA, Yandle TG, Charles CJ, Richards AM. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol. 2000;167:239-246.
ABSTRACT
35. Sengenes C, Zakaroff-Girard A, Moulin A, et al. Natriuretic peptide–dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol. 2002;283:R257-R265.
FREE FULL TEXT
36. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-1351.
FREE FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Frankenstein et al.
Eur Heart J 2008;29:2634-2640.
ABSTRACT
| FULL TEXT
Relation Between Body Mass Index, Waist Circumference, and Death After Acute Myocardial Infarction
Zeller et al.
Circulation 2008;118:482-490.
ABSTRACT
| FULL TEXT
Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure
Waldo et al.
J Am Coll Cardiol 2008;51:1874-1882.
ABSTRACT
| FULL TEXT
Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations
Meirhaeghe et al.
Hum Mol Genet 2007;16:1343-1350.
ABSTRACT
| FULL TEXT
Short-Term Serial Sampling of Natriuretic Peptides in Patients Presenting With Chest Pain
Kwan et al.
J Am Coll Cardiol 2007;49:1186-1192.
ABSTRACT
| FULL TEXT
Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea
Bayes-Genis et al.
Arch Intern Med 2007;167:400-407.
ABSTRACT
| FULL TEXT
Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea.
Mueller et al.
Arch Intern Med 2006;166:1081-1087.
ABSTRACT
| FULL TEXT
B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass Surgery
St. Peter et al.
Clin. Chem. 2006;52:680-685.
ABSTRACT
| FULL TEXT
Is Brain Natriuretic Peptide Production Decreased in Obese Subjects?
van Kimmenade et al.
J Am Coll Cardiol 2006;47:886-887.
FULL TEXT
B-Type Natriuretic Peptide Levels in Obese Patients With Advanced Heart Failure |
